Please ensure Javascript is enabled for purposes of website accessibility

Study Finds Breast Cancer Risk Can Rise by 50% for Women Who Drink a Cup of Milk Every Day

By David Jagielski - Feb 25, 2020 at 9:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Researchers didn't notice a heightened risk among people who consumed soy milk.

A new study released this month in the International Journal of Epidemiology has found that women who drink milk every day may be at an elevated risk of developing breast cancer. The observational study followed 52,795 women in North America over a period of 7.9 years, and one of the key findings, according to the study's author, Dr. Gary Fraser, was that "by drinking up to one cup per day, the associated risk went up to 50 percent, and for those drinking two to three cups per day, the risk increased further to 70 percent to 80 percent."Researchers found that soy products, however, weren't associated with a higher risk of breast cancer.

By the end of the study, there were 1,057 women diagnosed with breast cancer, or about 2% of the total women in the study. Currently, there's about a 13% risk that an American woman will develop breast cancer at some point during her life.  

The American Cancer Society (ACS) estimates that 42,170 women will die from breast cancer in 2020.  It's the second leading cause of cancer death in women behind lung cancer, to which the ACS estimates 63,220 American women will succumb this year. 

Doctor reviewing test results with cancer patient.

Image source: Getty Images.

Breast cancer patients may soon have another option

Biotech company Seattle Genetics (SGEN -2.73%) is working on bringing a new breast cancer drug to market, tucatinib. The drug treats HER2-positive breast cancer, an aggressive form of cancer that can grow and divide rapidly. Approximately one in five breast cancers fall into this classification. Seattle Genetics applied for a new drug application late last year, and the Food and Drug Administration announced earlier this month that it has granted the drug a priority review. 

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$165.50 (-2.73%) $-4.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.